Compounded vs Brand-Name GLP-1: The Real Cost Difference

The price gap between brand-name and compounded GLP-1 medication is the widest in the whole category, and it is where most of the confusion lives. This guide lays out what each option actually costs, what the money buys, and where the trade-offs are — so you can decide on value rather than on whichever number you saw first.

The brand-name price: Wegovy and Zepbound

The FDA-approved brand-name options are Wegovy (semaglutide 2.4 mg), approved for chronic weight management in 2021¹, and Zepbound (tirzepatide), approved in 2023². Their manufacturer list prices sit in roughly the $1,000–$1,350-per-month range before insurance or manufacturer savings programs. If your insurance covers weight-management medication, your out-of-pocket cost can fall dramatically — sometimes to a modest copay. If it does not, that list price is what you face, and coverage for obesity medication remains inconsistent — though both manufacturers now run direct self-pay channels well below list, which we cover in how much a GLP-1 costs without insurance. For the full breakdown of Zepbound's cash price specifically, plus the manufacturer's self-pay channel, see the Zepbound cost page.

The compounded price: what telehealth actually charges

Compounded semaglutide and tirzepatide are prepared by compounding pharmacies and sold cash-pay through telehealth. Across the providers we track, disclosed monthly prices run from about $65 to $349 per month, depending on the molecule, the provider, and your dose — a fraction of brand-name list pricing. That is the entire reason the compounded market exists at this scale. You can model your own number in the cost calculators, and we break the ranges down in what compounded GLP-1 actually costs per month. If tirzepatide is your molecule, the full annual ranking of compounded tirzepatide by twelve-month cost is at cheapest tirzepatide over 12 months.

Same molecule, different regulatory status

Here is the part that matters. Brand-name and compounded products can use the same active ingredient — semaglutide or tirzepatide — and the efficacy evidence for those molecules is strong: semaglutide 2.4 mg drove about 15% mean weight loss in its pivotal trial³, and tirzepatide up to about 21% in its own⁴. But those trials studied the brand-name, FDA-approved products. Compounded versions are not FDA-approved, and the FDA does not verify the safety, effectiveness, or quality of compounded drugs⁵. The molecule may be the same on paper; the regulatory assurance is not. That is the real trade behind the price gap — and for tirzepatide specifically, the legal basis for that compounding has narrowed since the drug came off the FDA's shortage list; see is compounded tirzepatide still legal for exactly what changed and what pathway remains.

A different molecule sometimes shows up in this same compounded-pricing conversation with a much bigger efficacy claim attached: retatrutide. It is not FDA-approved at all, for any indication, which puts it in a materially different and riskier category than a compounded copy of an approved molecule — see retatrutide vs tirzepatide before treating the two as comparable options.

So what are you actually paying for?

Brand-name pricing buys FDA-verified manufacturing, a consistent supply chain, and — if you have coverage — the possibility that insurance absorbs most of the cost. Compounded pricing buys access at cash-pay rates most people can actually sustain month to month. Neither is automatically the "right" answer.

A handful of telehealth programs sell both sides of this trade from one account, which is the cleanest way to see the gap in a single price list. Luvo Health publishes its whole menu openly: compounded semaglutide injection at $249 and compounded tirzepatide injection at $339, with brand Ozempic® at $1,299 and Zepbound® at $1,399 sitting on the same page. Read those figures carefully before you compare them with anything else on this site — Luvo bills every four weeks rather than every calendar month, so a year is thirteen of those charges, not twelve. The honest framing is: if your insurance covers a brand-name GLP-1, that is often both the safest and, net of coverage, the cheapest route. If it does not, compounded medication from a verifiable, LegitScript-certified pharmacy is what makes treatment affordable for many people — provided you understand what FDA approval you are giving up.

Do the year-one math, not the month-one math

Whichever side you land on, compare total annual cost, not the first sticker you see. For brand-name, that means confirming your actual copay after any savings program. For compounded, it means checking for teaser rates that step up after month one and adding dose-escalation costs — the full method is in the true monthly cost of GLP-1. Then vet each one against our provider checklist, rank your finalists across the full provider review index and settle it on the compare tool. The trial and pricing sources behind every figure here are in our research library.